3-Methyladenine (3-MA)

For research use only. Not for use in humans.

目录号：S2767 别名： NSC 66389

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA)是一种选择性PI3K抑制剂，作用于Vps34和PI3Kγ，在 HeLa细胞中IC50分别为25 μM和60 μM；永久性抑制I型PI3K，但对III型PI3K的抑制是短暂的，也会阻断自噬体的形成。3-Methyladenine (3-MA)可成功应用于抑制线粒体自噬。现配现用（加热助溶）。

规格 价格 库存 购买数量  
RMB 579.66 现货
RMB 3010.37 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的3-Methyladenine (3-MA)发表文献448篇：

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 3-Methyladenine (3-MA)是一种选择性PI3K抑制剂，作用于Vps34和PI3Kγ，在 HeLa细胞中IC50分别为25 μM和60 μM；永久性抑制I型PI3K，但对III型PI3K的抑制是短暂的，也会阻断自噬体的形成。3-Methyladenine (3-MA)可成功应用于抑制线粒体自噬。现配现用（加热助溶）。
靶点
Vps34 [1]
(HeLa cells)		 PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
体外研究

3-MA对Vps34轻微的偏向性可能是由于Vps34中某个特异性的疏水环形结构可以环绕在3-MA的3-甲基基团外面造成的[1] 。据报道对于正常培养和饥饿处理的癌细胞3-MA都能引起细胞死亡。3-MA还可以不通过抑制自吞噬来抑制细胞迁移和入侵，这表明3-MA 除了抑制自吞噬之外还有其它生物功能。3-MA可以造成半胱天冬酶依赖的细胞死亡，这一功能与它对自吞噬的抑制无关。用5mM 3-MA处理葡萄糖饥饿Hela细胞可降低gfp-lc3阳性细胞比例至23%。3-MA处理细胞12到48小时内 LC3-I 的水平上升而LC3-II 水平下降。LC3-I转为为 LC3-II 的过程被3-MA抑制了。 2.5 mM 或5 mM 3-MA 处理HeLa 细胞一天并不影响细胞存活率, 而 10 mM 3-MA 处理一天会造成细胞存活率下降25.0% 。 2.5, 5 或 10 mM 3-MA 处理细胞两天分别使细胞存活率下降 11.5%, 38.0% 和79.4% 。3-MA 降低细胞存活率的作用具有时间和剂量依赖特性。3-MA 明显缩短nocodazole诱导的前中期阻断时间[2]。3-MA 通过抑制自吞噬来抑制SU11274诱导的细胞死亡[3]。 在野生型MEF细胞中延长 3-MA处理时间 (最多 9 小时) 明显造成 LC3 I 到 II 转换。延长 3-MA处理时间会明显增加GFP-LC3的聚集而wortmannin不具有此功能。3-MA介导的LC3 转换和游离 GFP 释放是ATG7依赖的。 3-MA处理会导致 p62 蛋白水平明显升高。即使在Atg5−/− 的MEF细胞中3-MA 也会使p62 水平升高，就像在DOX介导的ATG5缺失的细胞中一样 。3-MA以不同方式抑制 I 型和 III型 PI3K。与野生型细胞相比，在Tsc2−/−细胞中3-MA诱导的 LC3 I 到 LC3 II 转换过程大幅下降。3-MA会破坏mTOR复合物1的拮抗自吞噬功能[4]。
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX6zcW0> MWOybC=> NULPUFlGTE2VTx?= Mo\UdoVlfWOnczDndo94fGhiaX7obYJqfG:{eTDl[oZm[3Rib3[gRmROSw>? Mk[3NlU4OTZ3NkG=
A549  NY\CV|E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[zcW0> M1\2[lJp NUXFN|luTE2VTx?= NF\pOoZz\WS3Y3XzJIdzd3e2aDDpcohq[mm2b4L5JIVn\mWldDDv[kBDTE2F NVTpUXNJOjV5MU[1OlE>
95D NWLvUIs{SXCxcITvd4l{KEG|c3H5 NFi5WWw2dU1? NFXGZXkzcA>? MXjEUXNQ MUnpcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh? M{XYbVI2PzF4NU[x
A549  MojORZBweHSxc3nzJGF{e2G7 NXvGUFRiPW2P NYHjWHoxOmh? MUXEUXNQ MYLpcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh? MoTnNlU4OTZ3NkG=
NBL-W-S  MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[zNY1O MonoOog> MXzlcohidmOnczDHRW5VNTZzIITvfIlkcXS7 M{jCWFI2OzJ|MkKy
NBL-W-S  MmG0RZBweHSxc3nzJGF{e2G7 MVmxcW0> MmO0Oog> MmjTbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgS2FPXC14MR?= M4P3bVI2OzJ|MkKy
A2780cp  NV[yPYFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDZNpMydU1? MU[xbC=> M160bIlv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp NHjhfI0zPTN{Mk[5OC=>
A549  MVnGeY5kfGmxbjDBd5NigQ>? NWDRN|BFPW2P NIfaSmczcA>? M2PZWpN2eHC{ZYPz[ZMhW1CFIHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEyFMz3JTS=> NV3H[ZNnOjV{OEW2Nlg>
H157 NW\xUoQyTnWwY4Tpc44hSXO|YYm= NXXJTJVpPW2P M1m0NFJp MWfzeZBxemW|c3XzJHNRSyCrbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBNSzNvSVm= MlPQNlUzQDV4Mki=
MDR NEDmR2ZCeG:ydH;zbZMhSXO|YYm= M2fRe|ExdU1? Moj0Oog> MYLzeJJmdme2aHXud{B1cGVicH;3[ZIhd2ZiYX70bYNidmOncjDkdpVoew>? MXqyOVAyQTdyMR?=
HT-29  M2rFcWFxd3C2b4Ppd{BCe3OjeR?= MoLLNY1O NVLLR5VNPDiq Mk[4SG1UVw>? Mk\S[Y5p[W6lZYOgZo9zfGW8b33pZk1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> NXzOdXVTOjR6NEKxOVg>
Microglia  NV\6XZQ2SXCxcITvd4l{KEG|c3H5 NXf4S3BJPW2P NYnHZXpIOjSq Mkiz[IVkemWjc3XzJIh6eG:6aXGtbY5lfWOnZDDj[YxtKGSnYYTo NHvhWlczPDhzOE[wNS=>
A2780cp M13t[WFxd3C2b4Ppd{BCe3OjeR?= MlrmNk42dU1? M2[0blFp MYnk[GgzVw>? NFTzU4ZmdmijbnPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp NWq1O5ZWOjR6MUe5OFY>
HepG2 MmPPSpVv[3Srb36gRZN{[Xl? MnvFOY1O MUO0bC=> MorIbY5kemWjc3XzJGhNKHKnbHXhd4U> NIOxUGQzPDdzM{W4Oy=>
A549 NIWzUWJCeG:ydH;zbZMhSXO|YYm= MkDZOY1O MVy0PIg> MXTk[YNz\WG|ZYOgeIhmKHCncnPlcpRi\2Vib3[gZ4VtdCCmZXH0bEBidmRiZYjwdoV{e2mxbjDs[ZZmdHNib3[gZ4F{eGG|ZT2zMEBD\WOuaX6tNUBidmRiTFOzMWlK NHSzUpUzPDdyNkOwNy=>
U2OS M{Xi[GFxd3C2b4Ppd{BCe3OjeR?= NWrG[ItvOTCvTR?= MY[yOIg> M1XFVYlvfGWwc3nmbYV{KHSqZTDndo94fGhiaX7obYJqfGmxbjDv[kB1cGViVULPV{Bk\WyuczDpcoR2[2WmIHL5JGRwgA>? MljnNlQ3OzlyMUO=
Saos-2 NVnJWlJPSXCxcITvd4l{KEG|c3H5 MkjFNVBuVQ>? NHTFeI8zPGh? NELzS3RqdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gc4YhfGinIGWyU3Mh[2WubIOgbY5lfWOnZDDifUBFd3h? NYXoV4J6OjR4M{mwNVM>
A549 MkDpRZBweHSxc3nzJGF{e2G7 Mnu3NVBuVQ>? M1jVXVQ5cA>? NHSwRYdi[2OnbHXyZZRmeyC2aHWgdoVlfWO2aX;uJI9nKGOnbHygeoli[mmuaYT5JIlv\HWlZXSgZpkhWFS[ NHj3[FUzPDZ{NkeyNi=>
HCT116  NV\xcVJLSXCxcITvd4l{KEG|c3H5 M3fVUlVuVQ>? M1\VW|I1cA>? NEj3[pFmdmijbnPld{B1cGViYYDvdJRwe2m|IHnu[JVk\WRiYomgZZBq\2WwaX6= NVLtbHlsOjR4Mk[1NlI>
HGC-27 NX;Qe2NKTnWwY4Tpc44hSXO|YYm= M3XFV|ExdU1? NF[yNYYycA>? Mk\NbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIxwe3NiYomgVmFFODBzIH;yJG1MNTJ{ME[= NVjYbYdUOjR2MU[zOFk>
U2OS  M3PZc2Z2dmO2aX;uJGF{e2G7 MX:wMlUwOW2P Mmf4OFhp NHXoNldqdmS3Y3XzJJNidGmwb335Z4lvNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? NHP2O4MzPDN3OEO0Ni=>
MG-63 NVvoXVdLTnWwY4Tpc44hSXO|YYm= M{j6e|AvPS9zbV2= NV;IPHVtPDiq MkXubY5lfWOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> NY[wU2FDOjR|NUizOFI>
MG-63 MmX5RZBweHSxc3nzJGF{e2G7 M3HHO|AvPS9zbV2= NHXJbYU{Omh? NITHR49mdmijbnPld{B{[Wyrbn;tfYNqdi2rbnT1Z4VlKGOnbHygZZBweHSxc3nz NWXBWo5[OjR|NUizOFI>
MG-63 NGLJbmxCeG:ydH;zbZMhSXO|YYm= NVTvR2xoOTCvTR?= MlrFNVJp NF[0PWdmdmijbnPld{BFWC2rbnT1Z4VlKGGyb4D0c5Nqew>? Mn3CNlQ{PTh|MEG=
NTUB1 MnezRZBweHSxc3nzJGF{e2G7 MX[1cW0> MorQNU42cA>? M3TjbpBwfGWwdHnheIV{KGOnbHXjc5hq[i2rbnT1Z4VlKGGyb4D0c5Nqew>? NFnDUnkzPDN2OUG3Oi=>
T24 NH20O4tCeG:ydH;zbZMhSXO|YYm= MV21cW0> MkG1NU42cA>? M4DjNZBwfGWwdHnheIV{KGOnbHXjc5hq[i2rbnT1Z4VlKGGyb4D0c5Nqew>? Mo\rNlQ{PDlzN{[=
SGC-7901  NWfXOVJjSXCxcITvd4l{KEG|c3H5 M{fxO|JuVQ>? MorpNYg> M{L5NYlv[3KnYYPld{BESS12IHnu[JVk\WRiYYDvdJRwe2m| NH;WNJEzPDN{MUO0NC=>
SMMC-7721 NUnmZ2ExSXCxcITvd4l{KEG|c3H5 M13jelJuVQ>? NH[5cGEycA>? M1\TeYlv[3KnYYPld{BESS12IHnu[JVk\WRiYYDvdJRwe2m| MnzYNlQ{OjF|NEC=
ECSCs  NXjRd3FmSXCxcITvd4l{KEG|c3H5 NIKyWnEyOG2P NWTsOHhCPGh? MVHk[YNz\WG|ZYOgdoFx[W27Y3nuMZRz\WG2ZXSgZZBweHSxc3nz M3fVPVI1OzF7MUC5
MCF-7  MULGeY5kfGmxbjDBd5NigQ>? NYDqfWt3OTCvTR?= NVPkR2FUOjSq NHX0RoZqdmirYnn0d{B1cGViYYX0c5Bp[We7IHnu[JVk\WRiYomgZ4hmdW:2aHXyZZB6KGS{dXfz NITpUYgzPDNzNUW3PC=>
UOK257 NUP1Tm1OSXCxcITvd4l{KEG|c3H5 MnXKOY1O MYKzbC=> NYjtfo5w\W6qYX7j[ZMheGGlbHn0ZZhmdC2vZXTpZZRm\CCjcH;weI9{cXQEoB?= MYOyOFMxPTZyNB?=
ACHN-5968 MVPBdI9xfG:|aYOgRZN{[Xl? MXG1cW0> M4PZbVNp NED5TIRmdmijbnPld{Bx[WOuaYThfIVtNW2nZHnheIVlKGGyb4D0c5Nqe8Li MmXINlQ{ODV4MES=
Huh7 NFzTbmtCeG:ydH;zbZMhSXO|YYm= NGjyN3IzdU1? NFe1ZlEyOmh? MWPEUXNQ M4nYRYlvcGmkaYTzJGFbTDhyNUWtbY5lfWOnZDDj[YxtKGSnYYTo M4LBfVI1Ojl5M{Cw
Hep3B NXjUOVh[SXCxcITvd4l{KEG|c3H5 MmjPNo1O MYCxNog> NXK4RlN3TE2VTx?= NIr2V25qdmirYnn0d{BCYkR6MEW1MYlv\HWlZXSgZ4VtdCCmZXH0bC=> MVOyOFI6PzNyMB?=
RKO MljhSpVv[3Srb36gRZN{[Xl? NUfFUoZnOm2P MX:xbC=> Mo[5SG1UVw>? NE\QcIJmdmijbnPld{Bk\WyuIHTlZZRpKGK7IHflcIRidmGveXPpci=> MYSyOFI6OTd5Nx?=
HepG2 E47 NWHMXJdiTnWwY4Tpc44hSXO|YYm= NWH0e2NGOi53bV2= MnnrOFhp M33Mfolv[3KnYYPld{B1cGVidH;4bYNqfHlib3[gRWEtKEKVTzygZY5lKEOFbES= M1nVZlI1Ojd|N{O4
LoVo  M3S0NWFxd3C2b4Ppd{BCe3OjeR?= NE\3dGs2dU1? NYDzeZJHPDiq MkG4[Y5p[W6lZYOgSGNCNWmwZIXj[YQh[XCxcITvd4l{Ng>? NUfrWW1mOjR{MEG4NVI>
WiDr NH6zXWdHfW6ldHnvckBCe3OjeR?= MUixNI1O NHHYZXUycA>? M3;lcolvcGmkaYTzJHBESkxvaX7keYNm\CCOQ{OgTWkh\XiycnXzd4lwdg>? M4HYb|I1OTlyNEi5
H1299  NVTQTXhPTnWwY4Tpc44hSXO|YYm= MmLaNVBuVQ>? M1na[VRp MV\pcoNz\WG|ZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NIXIXlczPDF5M{KwPC=>
H460 M{PNbmZ2dmO2aX;uJGF{e2G7 MV6xNI1O MXK0bC=> M4rrTYlv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp M1H3NlI1OTd|MkC4
A549 NXnJZlZtTnWwY4Tpc44hSXO|YYm= NGrLO4cyOG2P NX7GTXp[PGh? MoribY5pcWKrdIOgZZV1d3CqYXf5JIlv\HWlZXSgZpkhcXK{YXTpZZRqd25? NXf5S5dPOjRzNEK3N|U>
Hep3B NF7rWG9CeG:ydH;zbZMhSXO|YYm= M4O2OVVuVQ>? M1jDOFI1cA>? NUnh[|Zq[XS2ZX71ZZRmeyCWTl[t{tEheHKxdHXjeIlwdiCjZ3HpcpN1KHOncoXtJJN1[XK4YYTpc44udWWmaXH0[YQh[XCxcITvd4l{ NHnHXlAzPDB4Nk[5Ny=>
SMMC-7721 MX3BdI9xfG:|aYOgRZN{[Xl? M1;2O|VuVQ>? M2D5OFI1cA>? MkXHZZR1\W63YYTld{BVVkZvzsGgdJJwfGWldHnvckBi\2GrboP0JJNmenWvIIP0ZZJ3[XSrb36tcYVlcWG2ZXSgZZBweHSxc3nz NVz3T5NXOjRyNk[2PVM>
HO8910 NVvqflNmSXCxcITvd4l{KEG|c3H5 MWOxNI1O M3nxZVEzcA>? MVnlcohidmOnczDCNVkucW6mdXPl[EBieG:ydH;zbS=> M4Tt[VI{QTh|NkGw
MCF7 MoHhSpVv[3Srb36gRZN{[Xl? MlvOOY1O MlHuNlRp MV3pcoNz\WG|ZYOgR5VQKGmwZIXj[YQh[2WubDDk[YF1cA>? M3nNOlI{QTZ{NkK5
HONE-1  NIHBTpdHfW6ldHnvckBCe3OjeR?= M2XEUVVuVQ>? MmOxNYg> M2PjcJJmeHKnc4Pld{A3ei2vZXTpZZRm\CCUT2OgdJJw\HWldHnvci=> NILLbGUzOzh7MkO1PC=>
HeLa MlP4SpVv[3Srb36gRZN{[Xl? Ml;uNVBuVQ>? MlLNNog> NF3IVoN{fXCycnXzd4V{KEyFMzDJTUBmgHC{ZYPzbZNwdg>? M1;1eFI{QDZ2N{O4
HepG2 MXjGeY5kfGmxbjDBd5NigQ>? Mlu4NVBuVQ>? NHrYXpozPGh? Mm\1bY5pcWKrdIOgd4lVUUeDUj2gZY5lKEiEU2OtbY5lfWOnZDDheZRweGijZ4m= NVjST3B1OjN6MUewOFA>
SH-SY5Y M3Xte2Z2dmO2aX;uJGF{e2G7 MlrONY1O NVfOZmRMOjSq MX;pcohq[mm2czD0bIUh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF;DVC=> NVHSenJUOjN5NEOxOFg>
SH-SY5Y M1n6R2Fxd3C2b4Ppd{BCe3OjeR?= NVXYXXllPW2P NITsUVEycA>? MXLhZo9tcXOqZYOgZ4Vt[XO2cn;sJI5mfXKxcILveIVkfGm4ZTDl[oZm[3R? MXuyN|YyQTN7NR?=
PC12  NH;WT5RHfW6ldHnvckBCe3OjeR?= M1Ky[|ExdU1? MXuyOIg> M2LqOZdifGW{ NV;0SmlbyqCrbnjpZol1eyClaIntc5RzgXC|aX6tcIls\SCycn;0[YF{d22jbDDhZ5Rqfmm2eT6= NX7Qd4FxOjN4MEO5O|k>
OV2008 M{DOUmFxd3C2b4Ppd{BCe3OjeR?= MWm1cW0> M1rUcFI1cA>? MWHjc453\XK2czDGWHk4OjBid3n0bEBETESSIHnueI8h[W5iYXTkbZRqfmViZX\m[YN1KHSxd3Hy[JMhc2mubHnu[{BwfmG{aXHuJINidmOncjDj[Yxtew>? NE\ObokzOzV7MkK4NS=>
A2780 NXr2WGdwSXCxcITvd4l{KEG|c3H5 MkjVOY1O MYSyOIg> MV;jc453\XK2czDGWHk4OjBid3n0bEBETESSIHnueI8h[W5iYXTkbZRqfmViZX\m[YN1KHSxd3Hy[JMhc2mubHnu[{BwfmG{aXHuJINidmOncjDj[Yxtew>? Mn\0NlM2QTJ{OEG=
Saos-2  MWXBdI9xfG:|aYOgRZN{[Xl? NIHWZpYydU1? M1SyTlk3cA>? MnvUbY5kemWjc3XzJINmdGxiZHXheIghcW6mdXPl[EBjgSCSQ2i= NInjNoMzOzV4M{G3NS=>
1321N1 NXPwOml1S3m2b4TvfIlkcXS7IFHzd4F6 MlziOY1O NH62VokzPGh? NXrHcI97eHKxdHXjeJMh[2WubDDh[4FqdnO2IGDDUk1qdmS3Y3XkJJRwgGmlaYT5 M2S3ZVI{PTJ3Mk[1
SH-SY5Y NX3mRnJyS3m2b4TvfIlkcXS7IFHzd4F6 NInib3E2dU1? MXGyOIg> MVXpcoNz\WG|ZYOgVGNPKHSxeHnjbZR6 NFTIWXEzOzV{NUK2OS=>
HT-29  NFmzd|BHfW6ldHnvckBCe3OjeR?= M2nBTlFuVQ>? M3HpUlQ5Nzl4aB?= M2PnNIlvcGmkaYTzJGFOWEtiaX7keYNmeyCjdYTvdIhi\2mlIHPlcIwh\GWjdHi= Ml;WNlM2ODh{N{K=
OR6 MYXGeY5kfGmxbjDBd5NigQ>? MU[xNI1O MYC3Nog> MVnzeZBxemW|c3XzJGhEXiC{ZYDsbYNifGmxbjDhcoQh\m:{bXH0bY9vKG:oIHH1eI9xcGGpb4PvcYV{ MkfJNlM{QTV6N{W=
Hela  MVLGeY5kfGmxbjDBd5NigQ>? M4\h[FVuVQ>? MlPnNlRp NX\6VWtUcW6qaXLpeJMhe3Sjco\heIlwdi2rbnT1Z4VlKGG3dH;wbIFogQ>? Mn3vNlM{QTV4N{m=
MCF-7  M2e3VWZ2dmO2aX;uJGF{e2G7 M3fVV|VuVQ>? M{HPTFI1cA>? M2jLUYlvcGmkaYTzJJN1[XK4YYTpc44ucW6mdXPl[EBifXSxcHjh[5k> NVPsZmNCOjN|OUW2O|k>
HUVECs NH7R[5hHfW6ldHnvckBCe3OjeR?= Mo[wN41O M1y4clI1cA>? NFmydIZjdG:la4OgeIhmKHC{b4TlZ5RqfmViZX\m[YN1KG:oIILld5ZmemG2cn;sJIJ6KGmwaHnibZRqdmdiYYX0c5Bp[We7 M3TJ[FI{OzV6OUK4
T24 MWjGeY5kfGmxbjDBd5NigQ>? Mm\VNVBuVQ>? NGnuUpEycA>? NV3rfpY{emWmdXPld{B1cGViY3zlZZZi\2Vib3[gUGM{KGGodHXyJIJicWOjbHnuJJRz\WG2bXXueC=> Mm[xNlM{PTRyOEC=
U251MG  M2PyeWZ2dmO2aX;uJGF{e2G7 MVOzcW0> NUH6TVdDOWh? M2jiRpN2eHC{ZYPz[ZMhVEN|LVnJJJBzd3SnaX6g[ZhxemW|c3nvci=> M{Xw[FI{OzN6NkG4
GTL-16  MmXmRZBweHSxc3nzJGF{e2G7 NGHobGk2dU1? M2WwNlI1cA>? M1PocpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYYOgZ49ueGG{ZXSgeI8h[2WubIOgeJJm[XSnZDD3bZRpKE2HVDDpcohq[mm2b4Lz MkSzNlM{OTN2OUC=
T-47D NXvRWIpTTnWwY4Tpc44hSXO|YYm= NVzyPVJQOTCvTR?= MVSybC=> NIrkRpNqdmirYnn0d{BifXSxcHjh[5kheHKxY3Xzd{BidmRiaX7jdoVie2W|IILhdIFugWOrbjDpcoR2[2WmIHHwc5B1d3Orcx?= NHnGWIwzOzNyMECyOi=>
PaCa44 M3rqPWFxd3C2b4Ppd{BCe3OjeR?= MlnMNk42dU1? NI[1R|MycA>? MmfZdoVlfWOnc9Mg[4VvcXCrbj3t[YRq[XSnZDDhdI9xfG:|aYO= NVK5XZJ2OjNzMkSxNVI>
MDA-MB231 NF3VVYdHfW6ldHnvckBCe3OjeR?= Mni4OY1O MkL6NYg> MmTlbY5kemWjc3XzJJJme3[ncnH0do9tNW2nZHnheIVlKGOjc4Dhd4Uh[WO2aY\heIlwdiCjbnSgZ4VtdCCmZXH0bC=> MnHWNlMxQDh6NUC=
HeLa MmLBRZBweHSxc3nzJGF{e2G7 MknnNVBuVQ>? M1vMd|Jp NWLOOGlo\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JINwNXS{ZXH0cYVvfCC5aYToJHBGUQ>? MlrSNlMxODBzM{W=
SK-HEP-1 Mn7lRZBweHSxc3nzJGF{e2G7 NFG4SnMyOG2P NWrh[4FUOWh? MmOwdJJwfGWldIOgZYdicW6|dDDheZRweGijZ4mgZY5lKGmwZIXj[ZMh[XCxcITvd4l{KGmwIHL1[oFtcW5vdILlZZRm\CClZXzsdy=> MXOyNlg2QDZ2OR?=
HepG2 M33TW2Fxd3C2b4Ppd{BCe3OjeR?= NXfsNmp{O22P MorzOYg> M{\ObpJm\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDRSJM> NHnPWYczOjh|NkW5OS=>
MCF-7  MoPPSpVv[3Srb36gRZN{[Xl? NVfoc4hnOm2P MmLKNlRp M1vHVIlvcGmkaYTzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KFSPwrC= MWGyOFk4ODZ5Nh?=
MDA-MB-231 M3vYOmZ2dmO2aX;uJGF{e2G7 MXmycW0> NE\JOoYzPGh? M3f6PYlvcGmkaYTzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KFSPwrC= M37xelI1QTdyNke2
MCF-7  NFTLWHZHfW6ldHnvckBCe3OjeR?= M1r2NlJuVQ>? NVnvZ4ppPDiq M3eydZBzd22xdHXzJHRONWmwZIXj[YQh[2WubDDk[YF1cA>? NXf5bnRFOjR7N{C2O|Y>
MDA-MB-231 NF;4Z2xHfW6ldHnvckBCe3OjeR?= NUfnZYtLOm2P MW[0PIg> M170fJBzd22xdHXzJHRONWmwZIXj[YQh[2WubDDk[YF1cA>? MX[yOFk4ODZ5Nh?=
PANC-1  MX;BdI9xfG:|aYOgRZN{[Xl? NFTkOI0ydU1? MUG0PIg> MWTEUXNQ NIfWd3ZmdmijbnPld{Bjd3K2ZYrvcYljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? M3Pjd|I1QDR{MUW4
MDA-MB 231 MUTBdI9xfG:|aYOgRZN{[Xl? M1;HdlVuVQ>? NEPGWG4xNjWq MnGzcY9lfWyjdHXzJHRw[2:vaX9CsuKhcW6mdXPl[EBieG:ydH;zbZM> Mk\1NlQ5OzB5OEG=
Microglia  NVjtPYFoSXCxcITvd4l{KEG|c3H5 M3\5SlVuVQ>? M{\MPFI1cA>? MkHJ[IVkemWjc3XzJIh6eG:6aXGtbY5lfWOnZDDj[YxtKGSnYYTo M1zvbVI1QDF6NkCx
A2780cp MojRRZBweHSxc3nzJGF{e2G7 MmK5Nk42dU1? MUCxbC=> MmDQ[IRJOk9? MYnlcohidmOnczDjbZNxdGG2aX6tbY5lfWOnZDDj[YxtKGSnYYTo M4PyfFI1QDF5OUS2
HepG2 NVXSZYFQTnWwY4Tpc44hSXO|YYm= M124eFVuVQ>? MonaOIg> NXPkdYs4cW6lcnXhd4V{KGOnbHz1cIFzKGyndnXsd{Bw\iCKTNMg NVTibHVXOjR5MUO1PFc>
U2OS MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXRRXoyOG2P MojQNlRp M2XIc4lvfGWwc3nmbYV{KHSqZTDndo94fGhiaX7obYJqfGmxbjDpcoR2[2WmIHL5JGRwgA>? NWe0Z|dNOjR4M{mwNVM>
HCT116 M3HvPGFxd3C2b4Ppd{BCe3OjeR?= MoXGOY1O MXeyOIg> M3TYUWROW09? NFXC[oFmdmijbnPld{BieGmpZX7pck1qdmS3Y3XkJINmdGxiZHXheIg> NUL2OHhWOjR4Mk[1NlI>
MCF-7  Mm[xRZBweHSxc3nzJGF{e2G7 MmPlNE4ydU1? MlS5Oog> MVXlcohidmOnczDzbZJ1cW6xbD3pcoR2[2WmIHHwc5B1d3Orcx?= NEfZbJgzOjd3MUm4PS=>
PC-3  NUPmUFZxSXCxcITvd4l{KEG|c3H5 MUiycW0> MkLMNog> NFfXepVqdmO{ZXHz[ZMhV1KLLXnu[JVk\WRiY3XscEBl\WG2aB?= NHLGS|IzOjd2NUW4NC=>
U251  NI\D[ZZCeG:ydH;zbZMhSXO|YYm= Mo\JOY1O NWL4cm0xOjSq NIfIe2lqdmO{ZXHz[ZMhWzFvaX7keYNm\CClZXzsJIRm[XSq M2q4fVIzPTd7N{i4
HeLa  MULBdI9xfG:|aYOgRZN{[Xl? Ml7POY1O M1XieFI1cA>? M2\2T4lv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZ4VtdCCmZXH0bC=> M4rPPFIzPTR3MUK4
A549 M4jZOmZ2dmO2aX;uJGF{e2G7 MUiwMlFuVQ>? MXyyOIg> MljPd5VxeHKnc4Pld{BUXTFzMke0MYlv\HWlZXSgZ4VtdCCmZXH0bC=> MYGyNlQ3Pjl4MB?=
pDCs M3vSW2Z2dmO2aX;uJGF{e2G7 NH;aR24yOG2P MYOwMlVp NGfJZmnDqHKnZIXj[ZMhfGinIHnu[JVkfGmxbjDv[kBKTk5vzsGgZpkhe3OUTlG0NC=> MYeyNlM6PjV7OR?=
BGC-823 NIHQWHRHfW6ldHnvckBCe3OjeR?= NGW1S4E2dU1? M1fHSVJp M2nHVolvcGmkaYTzJJRp\SC{YYTlJI9nKGG3dH;wbIFocWNiY3XscJM> MofDNlI{OjJzNUK=
U937 M3fXTGZ2dmO2aX;uJGF{e2G7 NEfkOlkzdU1? MnnsNVJp NFfx[oRl\WO{ZXHz[ZMhfGinIHH1eI9xcGGpeTDyZZRqd8Li NVXpOottOjJzNUWxOVA>
Marc-145 MVzGeY5kfGmxbjDBd5NigQ>? NXL5[nB2PW2P NUjHcW1YOTJxMkSvN|Zp MW\y[YR2[2W|IITo[UBRWlKVVjD0bZRmenNiYX7kJJRp\SCycn;0[YlvKGW6cILld5Nqd25? Mo\zNlIyOTl7MEC=
HBx  M4[wW2Fxd3C2b4Ppd{BCe3OjeR?= M1TuU|ExdU1? NWfOPWhlPDiq NVTDV41QTE2VTx?= MkTQbY5kemWjc3XzJINmdGxiZHXheIg> NFn5W|EzOjB{MEC3PC=>
MCF-7 MmDUSpVv[3Srb36gRZN{[Xl? Mo\mNVBuVQ>? MljoOFhp NIq2fmljdG:la4OgZZV1d3CqYXf5JIlv\HWlZXSgZpkh[m:{dHX6c41q[g>? M1nxUFIyQTNzOUO3
RMPI8226  MUnGeY5kfGmxbjDBd5NigQ>? Mli0OY1O M4fL[|Fp MnHLd5VxeHKnc4Pld{B1cGVibHX2[Ywhd2ZiYYX0c5Bp[We7IIXu[IVzKG63dILp[Y51KGSncHzleIlwdg>? MVyyNVkyPTZ{MB?=
PC12/TetOn MYHGeY5kfGmxbjDBd5NigQ>? MWiwMlEwOW2P NHP2[|UyQGh? MV3s[YFleyC2bzFOtU1{gW5qV2SpJIFk[3WvdXzheIlwdixidH;4bYNqfHluIHHu[EBwdGmpb33ldkBnd3KvYYTpc47DqA>? NVXxToN{OjF7ME[2OVk>
HeLa  MkXpR5l1d3SxeHnjbZR6KEG|c3H5 NWG1XJhzOm2P MoLDNlRp M3;6TIlvcGmkaYTld{B1cGViY4n0c5RwgGmlaYT5JI9nKHOrbHnibY5qdiC2bzDI[WxiKGOnbHzzMi=> NF\wdGYzOTh5NUO4OS=>
Jurkat M4Tje2Z2dmO2aX;uJGF{e2G7 M4nPVlExdU1? NXHtZoU1OWh? MoLt[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEOy2LSTDhcoQhfGinIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= MUeyNVg3PDB|Nx?=
K562 NGrxdohHfW6ldHnvckBCe3OjeR?= MV2xNI1O NEX5bm8ycA>? MWDk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUGM{NUmLIHHu[EB1cGViZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW| NVLxUXU2OjF6NkSwN|c>
Nara-H NGjmVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPRSINzPW2P NYDFNI9FPDiq NETFOmhmdmijbnPld{B1\W2|aYLvcIlufXOvZXTpZZRm\CC|dYDwdoV{e2mxbjDv[kBP[XKjLVigZ4VtdCCycn;sbYZmemG2aX;u MWiyNVgxPTB|Mx?=
HUVECs MVfGeY5kfGmxbjDBd5NigQ>? MUmxNI1O M1TnO|AvPWh? Ml33[IVkemWjc3XzJJRp\SCDR1WtRnNCcW6mdXPl[EBifXSxcHjh[5khdGW4ZR?= MoHjNlE1Pjh3OUK=
HepG2 Mk\IRZBweHSxc3nzJGF{e2G7 NWTobHVIOm2P M1f1UVFp M3y3RYVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJINmdGxiZHXheIg> MonPNlE1PTN4OUG=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
α-SMA / TGF-β / LC-3BI / LC-3B II / Beclin-1 / NF-κB p65; 

PubMed: 29296191     


Western blotting analysed expression of α-SMA, TGF-β, LC-3B, Beclin-1, NF-κB and NF-κBp65 in hepatic stellate cells.

caspase-3 / caspase-9 / PARP; 

PubMed: 25891159     


EC9706 cell lysates were prepared and subjected to immunoblotting with antibodies against caspase-3, caspase-9 and PARP. The expression ratios in each experiment were determined densitometrically. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; PI, propidum iodide; PARP, poly(ADP ribose) polymerase.

VEGF; 

PubMed: 25891159     


Effects of autophagy inhibition on the protein expression levels of VEGF. Western blot analysis demonstrated that VEGF protein expression levels were decreased when the EC9706 human esophageal squamous cell carcinoma cells were treated with 3-MA. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; VEGF, vascular endothelial growth factor.

APP / BACE1 / ADAM17 / Presenilin 1 / Presenilin 2 / Nicastrin / APH-1 / Pen-2 / LC3-1 / LC3-2; 

PubMed: 26316755     


Presenilin 1, Nicastrin, and Pen-2 were increased with the 3-MA treatment (*P<0.001) while the other component of the γ-secretase complex (APH-1 and Presenilin 2) has no difference. 3-MA, 3-methyladenine; Con, control; APP, amyloid protein precursor.

29296191 25891159 26316755
Immunofluorescence
LC3 / Hif-α / COX2; 

PubMed: 29039446     


Chemical interventions of autophagy and ischemic-hypoxic injury, assessed using immunochemical double labeling. Compared with the control group, expression levels of HIF-α and COX2 were altered by chemical intervention. (A) Chemical intervention altered the expression of HIF-α and autophagosmes. Following autophagy antagonist (3-MA) intervention, expression of HIF-α was enhanced, compared with that in the OGD group, and was decreased by the autophagy agonist, rapamycin. In the MHY treatment group, expression of HIF-α was similar to that in the 3-MA group. (B) Chemical intervention showed changes in the expression of COX2 and autophagosomes. Changes in the expression of COX2 were similar to changes in HIF-α. Scale bar, 30 µm. OGD, oxygen-glucose deprivation; HIF-α, hypoxia-inducible factor-α; COX2, cyclooxygenase 2; 3-MA, 3-methyladenine; RP, rapamycin; MHY, MHY1485.

29039446
Growth inhibition assay
Cell viability; 

PubMed: 26934124     


KYSE 180 cells were co-treated with EDHB (40 μg/ml) and various concentrations of 3-MA for 24 h (left) or 48 h (right), and cell viability was determined by WST-8 assays.

26934124
体内研究 3-Methyladenine (3-MA)可以通过对磷酸肌醇3磷酸激酶(PI3K) 的作用来阻断自吞噬, 而PI3K的活性对于自噬体形成早期膜池的成核和组装是必须的。与SAH 处理组相比3-MA并不会改变出血的程度。与SAH +对照成分组相比经过3-MA预处理后会明显加重神经病学症状。3-MA处理会减少自吞噬发生[5]。 相反地,在SAH + 3-MA组里 断裂的半胱天冬酶表达量明显上调，与此一致的是与SAH + 对照成分组相比，SAH + 3-MA组中右脑皮层里原位末端标记阳性细胞数量明显增多[5]。

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[4]
- 合并

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
细胞实验：[2]
- 合并
  • Cell lines: HeLa 细胞系
  • Concentrations: 1-10 mM
  • Incubation Time: 3 分钟
  • Method: 用台盼蓝染色法分析细胞存活率（如HeLa细胞）。简言之, 经过3-MA处理后将贴壁的与漂浮的细胞都用PBS( pH 7.4)重悬，密度控制在每毫升1-2×106。加入等体积的0.4% 台盼蓝并彻底混匀。室温孵育3分钟后用血细胞计数器对细胞计数分析。
    (Only for Reference)
动物实验：[5]
- 合并
  • Animal Models: 体重 300-350 g 的成年雄性Sprague–Dawley 大鼠
  • Dosages: 400 nM
  • Administration: 脑室给药
    (Only for Reference)

溶解度 (25°C)

体外 Water 10 mg/mL warmed (67.04 mM)
DMSO 3 mg/mL warmed (20.11 mM)
Ethanol '4 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 149.15
化学式

C6H7N5
CAS号 5142-23-4
储存条件 粉状
溶于溶剂
别名 NSC 66389

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • 回答：

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

Selleck产品目录册

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

  • Taselisib (GDC 0032) New

    Taselisib (GDC 0032)是一种有效，下一代的β亚型PI3K抑制剂，作用于PI3Kα/δ/γ， IC50分别为0.29 nM/0.12 nM/0.97nM，比作用于PI3Kβ选择性高10倍以上。

  • Pilaralisib (XL147) New

    Pilaralisib (XL147)是一种选择性的可逆I型PI3K抑制剂，作用于PI3Kα/δ/γ，在无细胞试验中IC50为 39 nM/36 nM/23 nM，对PI3Kβ作用较低。Phase 1/2。

  • GNE-317 New

    GNE-317 是一种有效的，大脑渗透性 PI3K 抑制剂。

  • LY294002

    LY294002 是首个合成的已知抑制PI3Kα/δ/β的小分子，在无细胞测定中IC50分别为 0.5 μM/0.57 μM/0.97 μM；在溶液中比在Wortmannin中稳定，也能够阻断自噬体的形成。它不仅能够结合class I PI3Ks和其他PI3K相关的激酶，还能够结合一些与PI3K家族无关的新型靶点。LY294002 可以抑制CK2，对应的IC50值为98 nM。LY294002 是一种非特异的 DNA-PKcs 抑制剂，并可激活自噬和凋亡。

    Features:LY294002是选择性的, 可渗透细胞的特定PI3K抑制剂，可作用于酶的ATP结合位点，且抑制自体吞噬的螯合作用。

  • Idelalisib (CAL-101, GS-1101)

    Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂，在无细胞试验中IC50为 2.5 nM；对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍，对p110δ的选择性是对 C2β，hVPS34，DNA-PK 和 mTOR的400到4000倍。Idelalisib 还可诱导自噬。

    Features:Calistoga 暗示 CAL-101治疗血液恶性肿瘤可能有更广泛的应用价值。

  • Wortmannin

    Wortmannin是一种首次命名的PI3K抑制剂，在无细胞试验中IC50为3 nM，对 PI3K 家族的选择性较低。Wortmannin 可抑制自噬体的形成，并有效抑制DNA-PK/ATM，在无细胞试验中IC50为16 nM和150 nM。Wortmannin 也能抑制 PLK1 的活性。

  • Dactolisib (BEZ235)

    Dactolisib (BEZ235, NVP-BEZ235) 是一种双重ATP竞争性 PI3K 和 mTOR 抑制剂，在无细胞试验中，抑制 p110α/γ/δ/β 和 mTOR(p70S6K) 的 IC50 分别为 4 nM /5 nM /7 nM /75 nM /6 nM。 在 3T3TopBP1-ER 细胞中抑制 ATR，IC50 为 21 nM，而对 Akt 和 PDK1 的抑制作用很弱。Dactolisib可诱导自噬并抑制HIV-1的复制。Phase 2。

  • Buparlisib (BKM120)

    Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂，在无细胞试验中作用于p110α/β/δ/γ的IC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34，mTOR，DNAPK 的作用效果下降，而对 PI4Kβ几乎没有活性。Buparlisib 可诱导凋亡。Phase 2。

    Features:BKM120是可用于口服的生物有效的PI3K抑制剂。

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941) 是一种有效的PI3Kα/δ抑制剂，在无细胞试验中IC50为 3 nM，对p110β (11倍)和p110γ (25倍)具有适度的选择性。Pictilisib (GDC-0941) 可诱导自噬和凋亡。Phase 2。

  • Alpelisib (BYL719)

    Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂，在无细胞试验中IC50为 5 nM，对PI3Kβ/γ/δ具有极弱的作用。Phase 2。

Tags: 购买3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)供应商 | 采购3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)价格 | 3-Methyladenine (3-MA)生产 | 订购3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID